'Excellent' Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
(MedPage Today) -- Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2024 Category: Hematology Source Type: news

Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC? Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

QT Imaging to deliver Breast Acoustic CT scanner to research centers
QT Imaging Holdings is delivering its Breast Acoustic CT scanner in collaboration with research centers in the U.S. and Canada. The company is collaborating with the Department of Radiation Oncology and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, and the University of Illinois, Urbana-Champaign. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach that can accurately identify early response of breast cancer patients to neoadjuvant ...
Source: AuntMinnie.com Headlines - March 14, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Is semiannual mammo after breast conserving surgery necessary?
Annual mammography with a clinical exam -- rather than semiannual -- is “likely sufficient” for women who have undergone breast-conserving surgery and were treated with neoadjuvant therapy, a study published March 2 in Surgical Oncology Insight has found. Researchers led by Ton Wang, MD, from Cedars-Sinai Medical Center in Los Angeles found insufficient evidence supporting the use of semiannual mammography in these women, with less than 2% of women developing locoregional recurrence on routine surveillance. “Semiannual mammography is associated with unnecessary benign biopsies, which may increase health care costs ...
Source: AuntMinnie.com Headlines - March 8, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties Womens Imaging Breast Imaging Source Type: news

Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news

In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
(MedPage Today) -- Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 28, 2024 Category: American Health Source Type: news

Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant benefit in terms of event-free survival (EFS), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2024 Category: Pharmaceuticals Source Type: news

Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news

Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
Mark Kris, MD, discusses the use of a checkpoint inhibitor and chemotherapy as neoadjuvant therapy for every patient with stage II and III lung cancer at the time of diagnosis.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2024 Category: Pharmaceuticals Source Type: news

A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
(MedPage Today) -- Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 3, 2024 Category: Hematology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer ctDNA Clearance Predicts Relapse Risk in Urothelial Cancer
New research shows that ctDNA clearance following neoadjuvant treatment of muscle-invasive urothelial cancer can help predict response to therapy and the risk for relapse.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 30, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news